Dermata Therapeutics Inc(DRMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

DRMA Dermata Therapeutics Inc

Market Closed 12-12 16:00:00 EST

2.63

-0.12

-4.36%

盘后2.63

+0.000.00%

19:45 EST

High2.81	Low2.61	Vol55.34K
Open2.80	D1 Closing2.75	Amplitude7.27%
Mkt Cap2.70M	Tradable Cap2.22M	Total Shares1.03M
T/O148.29K	T/O Rate6.56%	Tradable Shares843.40K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"DRMA","market":"US","secType":"STK","nameCN":"Dermata Therapeutics Inc","latestPrice":2.63,"timestamp":1765573200000,"preClose":2.75,"halted":0,"volume":55338,"hourTrading":{"tag":"盘后","latestPrice":2.63,"preClose":2.63,"latestTime":"19:45 EST","volume":418,"amount":1096.9598,"timestamp":1765586721968},"delay":0,"floatShares":843400,"shares":1026457,"eps":-16.195467,"marketStatus":"Market Closed","change":-0.12,"latestTime":"12-12 16:00:00 EST","open":2.8,"high":2.8099,"low":2.61,"amount":148288.55794260002,"amplitude":0.072691,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-16.195467,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1628827200000,"exchange":"NASDAQ","adjPreClose":2.75,"postHourTrading":{"tag":"盘后","latestPrice":2.63,"preClose":2.63,"latestTime":"19:45 EST","volume":418,"amount":1096.9598,"timestamp":1765586721968},"volumeRatio":0.08388297312305364},"requestUrl":"/m/hq/s/DRMA/wiki","defaultTab":"wiki","newsList":[{"id":"2586602406","title":"Dermata Therapeutics: Strategic Shift and Financial Stability Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2586602406","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586602406?lang=en_us&edition=fundamental","pubTime":"2025-11-26 04:25","pubTimestamp":1764102327,"startTime":"0","endTime":"0","summary":"Analyst Anthony Vendetti from Maxim Group maintained a Buy rating on Dermata Therapeutics and keeping the price target at $10.00. Anthony Vendetti ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/dermata-therapeutics-strategic-shift-and-financial-stability-support-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/dermata-therapeutics-strategic-shift-and-financial-stability-support-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DRMA"],"gpt_icon":0},{"id":"2586090491","title":"BRIEF-Dermata Therapeutics Inc Files For Mixed Shelf Of Up To $100 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2586090491","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586090491?lang=en_us&edition=fundamental","pubTime":"2025-11-25 02:13","pubTimestamp":1764008038,"startTime":"0","endTime":"0","summary":"BRIEF-Dermata Therapeutics Inc Files For Mixed Shelf Of Up To $100 Million Nov 24  - Dermata Therapeutics Inc DRMA.O:DERMATA THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $100 MILLION - SEC FILINGSource text: [ID:n0001493152-25-024720]Further company coverage: DRMA.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nFWN3X00F6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","DRMA","BK4007"],"gpt_icon":0},{"id":"2586499833","title":"Dermata Therapeutics files $100M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2586499833","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586499833?lang=en_us&edition=fundamental","pubTime":"2025-11-25 00:35","pubTimestamp":1764002108,"startTime":"0","endTime":"0","summary":"11:34 EST Dermata Therapeutics (DRMA) files $100M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-movi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dermata-therapeutics-files-100m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dermata-therapeutics-files-100m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","DRMA","BK4007"],"gpt_icon":0},{"id":"2584501939","title":"BRIEF-Dermata Therapeutics terminates license agreement with Villani dated March 31, 2017, says in SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2584501939","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584501939?lang=en_us&edition=fundamental","pubTime":"2025-11-18 19:08","pubTimestamp":1763464096,"startTime":"0","endTime":"0","summary":"BRIEF-Dermata Therapeutics terminates license agreement with Villani dated March 31, 2017, says in SEC FilingNov 18  - Dermata Therapeutics Inc DRMA.O:DERMATA THERAPEUTICS INC - ON NOV 17, TERMINATES LICENSE AGREEMENT WITH VILLANI DATED MARCH 31, 2017 - SEC FILINGDERMATA THERAPEUTICS INC - TERMINATION LINKED TO STRATEGIC SHIFT TO OTC SKIN CARE - SEC FILINGDERMATA THERAPEUTICS : VILLANI WILL NOT BE ENTITLED TO RECEIVE ANY FURTHER MILESTONES OR OTHER PAYMENTS DUE AFTER TERMINATION DATEFurther company coverage: DRMA.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nFWN3WU0G4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DRMA","BK4139","BK4539"],"gpt_icon":0},{"id":"2584939345","title":"Dermata Therapeutics Inc - Termination Linked to Strategic Shift to Otc Skin Care - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2584939345","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584939345?lang=en_us&edition=fundamental","pubTime":"2025-11-18 19:02","pubTimestamp":1763463760,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nFWN3WU0G4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4539","BK4139","DRMA"],"gpt_icon":0},{"id":"2584939312","title":"Dermata Therapeutics : Villani Will Not Be Entitled to Receive Any Further Milestones or Other Payments Due After Termination Date","url":"https://stock-news.laohu8.com/highlight/detail?id=2584939312","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584939312?lang=en_us&edition=fundamental","pubTime":"2025-11-18 19:02","pubTimestamp":1763463760,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nFWN3WU0G4:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","DRMA","BK4139","BK4539"],"gpt_icon":0},{"id":"2584802939","title":"Dermata Therapeutics Inc - on Nov 17, Terminates License Agreement With Villani Dated March 31, 2017 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2584802939","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584802939?lang=en_us&edition=fundamental","pubTime":"2025-11-18 19:02","pubTimestamp":1763463760,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nFWN3WU0G4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","DRMA","BK4139","BK4539"],"gpt_icon":0},{"id":"2583684986","title":"BRIEF-Dermata Therapeutics Announces Strategic Pivot To OTC Skin Care - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2583684986","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583684986?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:20","pubTimestamp":1763155231,"startTime":"0","endTime":"0","summary":"BRIEF-Dermata Therapeutics Announces Strategic Pivot To OTC Skin Care - SEC FilingNov 14  - Dermata Therapeutics Inc DRMA.O:DERMATA THERAPEUTICS INC - ANNOUNCES STRATEGIC PIVOT TO OTC SKIN CARE - SEC FILINGDERMATA THERAPEUTICS INC - TO LAUNCH FIRST OTC ACNE KIT MID-2026 - SEC FILINGSource text: [ID:n0001493152-25-023419]Further company coverage: DRMA.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nFWN3WQ12H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DRMA","BK4139","BK4539"],"gpt_icon":0},{"id":"2583868418","title":"Dermata Therapeutics Q3 net loss narrows as R&D expenses fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2583868418","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583868418?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:20","pubTimestamp":1763155226,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Q3 net loss narrows as R&D expenses fallOverviewDermata reports Q3 net loss of $1.7 mln, with decreased R&D expensesCompany shifts focus to OTC dermatology products, plans 2026 pr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nL1N3WQ13P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRMA","BK4139","BK4007","BK4539"],"gpt_icon":0},{"id":"2583684514","title":"Dermata Therapeutics Inc - to Launch First Otc Acne Kit Mid-2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2583684514","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583684514?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:18","pubTimestamp":1763155112,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nFWN3WQ12H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","DRMA","BK4007","BK4139"],"gpt_icon":0},{"id":"2583545684","title":"Dermata Therapeutics Inc - Announces Strategic Pivot to Otc Skin Care - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2583545684","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583545684?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:18","pubTimestamp":1763155112,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nFWN3WQ12H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","BK4539","DRMA"],"gpt_icon":0},{"id":"2583848586","title":"Dermata Therapeutics Announces Strategic Shift to Over-the-Counter Dermatology Market, Plans Mid-2026 Launch of Once-Weekly Acne Kit Featuring Spongilla Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2583848586","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583848586?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:10","pubTimestamp":1763154630,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Announces Strategic Shift to Over-the-Counter Dermatology Market, Plans Mid-2026 Launch of Once-Weekly Acne Kit Featuring Spongilla Technology. Dermata Therapeutics Inc. has announced a strategic shift from developing prescription dermatology products to focusing on over-the-counter  dermatology treatments. The company plans to launch its first OTC product, a once-weekly acne kit utilizing its Spongilla technology, in mid-2026. Preparations are underway for branding, packaging, and manufacturing of this product. Dermata intends to market the acne kit directly to consumers, estheticians, and dermatologists for in-office treatments. The company aims to build a scalable portfolio of products that combine medical-grade science with everyday convenience, targeting a broader consumer base through accessible, effective dermatologic solutions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to prov","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL82BDk7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","DRMA","BK4007"],"gpt_icon":0},{"id":"2583681083","title":"Dermata Therapeutics Q3 EPS $(1.65) Misses $(1.59) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583681083","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583681083?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:07","pubTimestamp":1763154446,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics (NASDAQ:DRMA) reported quarterly losses of $(1.65) per share which missed the analyst consensus estimate of $(1.59) by 3.77 percent. This is a 91.92 percent increase over losses of $(20.41) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48879885/dermata-therapeutics-q3-eps-1-65-misses-1-59-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Dermata Therapeutics Q3 EPS $(1.65) Misses $(1.59) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRMA"],"gpt_icon":0},{"id":"2581831008","title":"Dermata Therapeutics Increases Stock Offering by $1.79M","url":"https://stock-news.laohu8.com/highlight/detail?id=2581831008","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581831008?lang=en_us&edition=fundamental","pubTime":"2025-11-08 05:38","pubTimestamp":1762551535,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics ( ($DRMA) ) just unveiled an update. On November 7, 2025, Dermata Therapeutics announced an increase in the maximum aggregate ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/dermata-therapeutics-increases-stock-offering-by-1-79m?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/dermata-therapeutics-increases-stock-offering-by-1-79m?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DRMA","BK4007","BK4139","BK4539"],"gpt_icon":0},{"id":"2572514934","title":"Dermata Therapeutics’ Spongilla Acne Treatment Patent Application Accepted by Australian Patent Office","url":"https://stock-news.laohu8.com/highlight/detail?id=2572514934","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572514934?lang=en_us&edition=fundamental","pubTime":"2025-10-02 20:00","pubTimestamp":1759406417,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Inc. announced that the Australian Patent Office has accepted its patent application for a combination of Spongilla technology as a method for treating acne. The accepted application, titled \"Compositions and methods for the treatment of skin conditions\" , marks a key step in expanding the company's international intellectual property portfolio. The patent is expected to be officially issued in mid-January 2026, provided no opposition is filed within three months of publication. This development follows a similar patent issued in the United States, strengthening Dermata's position in advancing next-generation acne treatments.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the ori","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251002:nNDL6CgD9j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRMA","BK4007","BK4139","BK4539"],"gpt_icon":0},{"id":"2568608074","title":"Dermata Therapeutics Presents Promising Phase 3 Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2568608074","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568608074?lang=en_us&edition=fundamental","pubTime":"2025-09-17 18:29","pubTimestamp":1758104971,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics ( ($DRMA) ) has provided an update. On September 17, 2025, Dermata Therapeutics presented clinical data from its Phase 3 STAR-...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/dermata-therapeutics-presents-promising-phase-3-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/dermata-therapeutics-presents-promising-phase-3-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DRMA","BK4139","BK4539","BK4007"],"gpt_icon":0},{"id":"2566983434","title":"BUZZ-U.S. STOCKS ON THE MOVE-Potbelly, Joby, Talen Energy","url":"https://stock-news.laohu8.com/highlight/detail?id=2566983434","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566983434?lang=en_us&edition=fundamental","pubTime":"2025-09-11 00:05","pubTimestamp":1757520303,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Potbelly, Joby, Talen EnergyEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nL6N3UX0RB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVDD","JOBY","WALD","EQT","FANG","PMVP","TVTX","GLSI","ASST","SNPS","APA","PBPB","FITB","AME","DNTH","VST","ALNY","LEA","CHWY","NKE","ACHC","BW","XOM","HPQ","TRML","LUCD","AMLX","HAL","RKT","NEM","DRMA","NVDU","BWA","GEV","RNA","CVX","DHR","RAL","TLN","CEG"],"gpt_icon":1},{"id":"2566606049","title":"BUZZ-Dermata Therapeutics climbs on acne product shift","url":"https://stock-news.laohu8.com/highlight/detail?id=2566606049","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566606049?lang=en_us&edition=fundamental","pubTime":"2025-09-10 20:32","pubTimestamp":1757507546,"startTime":"0","endTime":"0","summary":"BUZZ-Dermata Therapeutics climbs on acne product shift** Shares of drug developer Dermata Therapeutics DRMA.O rise 9.8% to $5.70 premarket** Co says it is shifting focus to over-the-counter dermatology products that can be sold directly to consumers** Co plans to develop a once-weekly acne kit using an approved OTC active ingredient combined with its Spongilla technology** The acne kit is expected to launch in mid-2026, co says** As part of its shift, co withdrew its marketing application for Xyngari from the FDA, a drug it was developing to treat moderate-to-severe rosacea** As of last close, stock down 61.6% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nL3N3UX0WP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","DRMA","BK4007"],"gpt_icon":0},{"id":"2566510606","title":"Dermata Therapeutics Inc - to Prioritize Development, Distribution of Otc Pharmaceutical Dermatology Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2566510606","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566510606?lang=en_us&edition=fundamental","pubTime":"2025-09-10 20:17","pubTimestamp":1757506670,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nFWN3UX0A6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","DRMA","BK4007"],"gpt_icon":0},{"id":"2566606846","title":"BRIEF-Dermata Withdraws FDA Application for Xyngari, Shifts Focus to OTC Skin Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2566606846","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566606846?lang=en_us&edition=fundamental","pubTime":"2025-09-10 20:09","pubTimestamp":1757506158,"startTime":"0","endTime":"0","summary":"BRIEF-Dermata Withdraws FDA Application for Xyngari, Shifts Focus to OTC Skin CareSept 10 (Reuters) - Dermata Therapeutics Inc DRMA.O:DERMATA THERAPEUTICS INC: HAS WITHDRAWN ITS INVESTIGATIONAL NEW DR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nFWN3UX0I3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","DRMA","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.dermatarx.com","stockEarnings":[{"period":"1week","weight":-0.0607},{"period":"1month","weight":-0.1571},{"period":"3month","weight":-0.5134},{"period":"6month","weight":-0.6308},{"period":"1year","weight":-0.7587},{"period":"ytd","weight":-0.8052}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.080502},{"month":2,"riseRate":0,"avgChangeRate":-0.160368},{"month":3,"riseRate":0.25,"avgChangeRate":-0.207822},{"month":4,"riseRate":0.25,"avgChangeRate":-0.08308},{"month":5,"riseRate":0,"avgChangeRate":-0.156549},{"month":6,"riseRate":0.25,"avgChangeRate":-0.174977},{"month":7,"riseRate":0.25,"avgChangeRate":-0.133285},{"month":8,"riseRate":0.25,"avgChangeRate":-0.03319},{"month":9,"riseRate":0,"avgChangeRate":-0.128292},{"month":10,"riseRate":0.4,"avgChangeRate":-0.136086},{"month":11,"riseRate":0.2,"avgChangeRate":-0.072999},{"month":12,"riseRate":0.2,"avgChangeRate":-0.174733}],"exchange":"NASDAQ","name":"Dermata Therapeutics Inc","nameEN":"Dermata Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Dermata Therapeutics Inc(DRMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Dermata Therapeutics Inc(DRMA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Dermata Therapeutics Inc,DRMA,Dermata Therapeutics Inc股票,Dermata Therapeutics Inc股票老虎,Dermata Therapeutics Inc股票老虎国际,Dermata Therapeutics Inc行情,Dermata Therapeutics Inc股票行情,Dermata Therapeutics Inc股价,Dermata Therapeutics Inc股市,Dermata Therapeutics Inc股票价格,Dermata Therapeutics Inc股票交易,Dermata Therapeutics Inc股票购买,Dermata Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Dermata Therapeutics Inc(DRMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Dermata Therapeutics Inc(DRMA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}